Rankings
▼
Calendar
VCEL
Vericel Corporation
$2B
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$30M
+35.6% YoY
Gross Profit
$21M
69.4% margin
Operating Income
$3M
10.2% margin
Net Income
$3M
11.4% margin
EPS (Diluted)
$0.07
QoQ Revenue Growth
+16.6%
Cash Flow
Operating Cash Flow
$8M
Free Cash Flow
$7M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$138M
Total Liabilities
$41M
Stockholders' Equity
$97M
Cash & Equivalents
$37M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$30M
$22M
+35.6%
Gross Profit
$21M
$14M
+47.6%
Operating Income
$3M
-$1M
+331.8%
Net Income
$3M
-$1M
+424.6%
Revenue Segments
Product
$30M
100%
← FY 2019
All Quarters
Q4 2019 →
VCEL Q3 2019 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena